ASP Isotopes Inc. discloses material events, capital structure, governance matters, operating results and project risks through its SEC filings. The company’s 8-K reports document business updates tied to isotope enrichment, PET Labs radiopharmaceutical operations, Quantum Leap Energy, research collaborations, advisory-board matters, and Renergen-related helium and LNG project disclosures.
Its filings also include Regulation FD exhibits, amended 8-K risk-factor disclosures, and a Form 12b-25 notice for annual-report timing. Recurring disclosure subjects include ASP and Quantum Enrichment technologies, Pretoria enrichment facilities, nuclear medicine and semiconductor isotope applications, nuclear fuel-cycle initiatives, financial position, forward-looking statements, permitting, development costs, and operational risks at the Virginia Gas Project.
ASP Isotopes Inc. (ASPI) reported third-quarter 2026 revenue of $5.124 million, versus $1.271 million a year earlier, while net loss attributable to shareholders widened to $30.371 million from $12.617 million. For the first nine months, revenue was $14.427 million versus $3.571 million; net loss from continuing operations was $91.567 million versus $96.802 million.
Net cash used in operating activities for the nine months was $66.449 million, compared with $19.935 million a year earlier. Cash and cash equivalents were $201.663 million at September 30, 2026; the company expects this cash to fund operating expenses and capital requirements for more than 12 months from issuance of the financial statements. Convertible notes payable at fair value were $85.860 million, compared with $199.323 million at December 31, 2025.
ASP Isotopes acquired Renergen in January 2026 and issued 14,270,000 shares in the acquisition. It deconsolidated Skyline on March 29, 2026, retaining approximately 8.6% of its outstanding Class A ordinary and preferred shares. Continuing operations include nuclear fuels, specialist isotopes and related services, and helium and LNG.
ASP Isotopes Inc. (ASPI) is the subject of Amendment No. 1 reporting zero beneficial ownership by Encompass Capital Advisors LLC and Todd J. Kantor. Encompass reports 0 shares (0%), and Kantor reports 0 shares (0.00%). Each reports zero sole and shared voting power and zero sole and shared dispositive power. Kantor is identified as Encompass Capital Advisors LLC’s managing member.
ASP Isotopes Inc. (ASPI) reported that AK Jensen Investment Management Limited beneficially owned 7,417,144 shares of the company's common stock, or 4.8% of the class. AK Jensen reported sole voting and dispositive power over 7,417,144 shares held by funds and accounts it manages. The percentage calculation uses 153,309,392 shares outstanding as of September 30, 2026.
ASP Isotopes Inc. announced that Tetra4 Proprietary Limited, a subsidiary of Renergen Limited, completed commissioning and achieved stable liquid helium production at the Virginia Gas Project. Liquid helium is accumulating in Tetra4’s cryogenic storage ahead of initial deliveries under existing offtake agreements.
Phase 1 is expected to produce approximately 2,500 GJ/day of LNG and approximately 70 Mcf/day of liquid helium. ASP Isotopes Executive Chairman and CEO Paul Mann, who is also Renergen’s CEO, said the project is ramping toward nameplate capacity, which is expected during the fourth quarter of 2026. Renergen’s principal asset is a 94.5% equity interest in Tetra4.
ASP Isotopes Inc. Chief Financial Officer Heather Kiessling reported that 21,830 common shares were sold at $2.19 per share. ASP Isotopes made the sale on her behalf under a mandatory sell-to-cover provision in her award agreement to cover minimum statutory tax withholding; the footnote says it was not her discretionary trade. She directly held 1,504,422 shares following the transaction. No Rule 10b5-1 plan is reported.
ASP Isotopes Inc. (ASPI) COO Robert Ainscow reported selling 22,500 shares of common stock at a weighted average price of $2.1140 per share; the shares were sold in multiple transactions at prices from $2.05 to $2.22. The sales were made under a Rule 10b5-1 trading plan adopted June 9, 2025, to cover tax withholding obligations connected with restricted stock award vesting. He reported holding 2,225,941 shares directly afterward.
ASP Isotopes Inc. is identified as issuer in a Rule 144 notice listing a proposed sale of 21,830 common shares for Heather Kiessling, identified as an affiliate. The shares have an aggregate market value of $47,975.09, with an approximate sale date of October 16, 2026. J.P. Morgan Securities LLC is listed as the broker, and NASDAQ as the exchange.
The notice also lists 400,000 common shares acquired by Kiessling as compensation through a restricted stock award on April 14, 2025. J.P. Morgan Securities LLC, Workplace Solutions, signed as agent and attorney in fact for Kiessling.
ASP Isotopes Inc. (ASPI) announced that its wholly owned subsidiary Quantum Leap Energy LLC (QLE), through a subsidiary, signed a binding Heads of Agreement with South Africa’s Nuclear Energy Corporation of South Africa SOC Limited (Necsa). The Agreement establishes a commercial framework for a joint venture to develop, finance, construct, commission, own and operate a test bench and commercial-scale HALEU production facility at Necsa’s Pelindaba site.
Under agreed principles, QLE will hold approximately 80% of the joint venture and lead operations and the arrangement of capital; Necsa will hold approximately 20% and contribute site access, nuclear safeguards, licensing and regulatory support. QLE says it has secured offtake for the HALEU the joint venture is expected to produce through supply agreements with TerraPower.
In July 2026, QLE received approval from South Africa’s Ministry of Electricity and Energy to acquire, possess, use, dispose of and transport source material and nuclear-related equipment and technology to advance uranium enrichment activities at Pelindaba. The test bench has been constructed, and refurbishment of its housing infrastructure is underway. QLE states it has not applied its enrichment technologies to U-235 or received permission or regulatory approval to test them on U-235, except for activities contemplated by the services contract with Necsa.
ASP Isotopes Inc. (ASPI) officer Robert Ainscow is expected to sell 22,500 common shares on October 14, 2026, under a Rule 10b5-1 trading plan. The stated aggregate market value is $46,575.00, based on the $2.07 closing market price on that date. The sale includes an amount for satisfying income tax liabilities from quarterly vesting of a previously granted 400,000-share restricted stock award, dated April 14, 2025.
ASP Isotopes Inc. reported that ENDRA Life Sciences filed a Form S-4 registration statement on October 2, 2026, relating to the proposed merger under the June 25, 2026 Agreement and Plan of Merger. Under the proposed structure, Kruger Merger Sub LLC, an ENDRA subsidiary, would merge into Noble Africa LLC, an ASP Isotopes subsidiary, with Noble Africa surviving as a direct, wholly owned subsidiary of ENDRA.
The proposed merger is subject to satisfaction or waiver of the conditions in the merger agreement. ENDRA’s S-4 contains a proxy statement and prospectus and includes information about Renergen, another ASP Isotopes subsidiary.